The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Artemisinin-Resistant Plasmodium falciparum Malaria
Open accessAbstract
For more than five decades, Southeast Asia (SEA) has been fertile ground for the emergence of drug-resistant Plasmodium falciparum malaria. After generating parasites resistant to chloroquine, sulfadoxine, pyrimethamine, quinine, and mefloquine, this region has now spawned parasites resistant to artemisinins, the world’s most potent antimalarial drugs. In areas where artemisinin resistance is prevalent, artemisinin combination therapies (ACTs)—the first-line treatments for malaria—are failing fast. This worrisome development threatens to make malaria practically untreatable in SEA, and threatens to compromise global endeavors to eliminate this disease. A recent series of clinical, in vitro , genomics, and transcriptomics studies in SEA have defined in vivo and in vitro phenotypes of artemisinin resistance, identified its causal genetic determinant, explored its molecular mechanism, and assessed its clinical impact. Specifically, these studies have established that artemisinin resistance manifests as slow parasite clearance in patients and increased survival of early-ring-stage parasites in vitro ; is caused by single nucleotide polymorphisms in the parasite’s K13 gene, is associated with an upregulated “unfolded protein response” pathway that may antagonize the pro-oxidant activity of artemisinins, and selects for partner drug resistance that rapidly leads to ACT failures. In SEA, clinical studies are urgently needed to monitor ACT efficacy where K13 mutations are prevalent, test whether new combinations of currently available drugs cure ACT failures, and advance new antimalarial compounds through preclinical pipelines and into clinical trials. Intensifying these efforts should help to forestall the spread of artemisinin and partner drug resistance from SEA to sub-Saharan Africa, where the world’s malaria transmission, morbidity, and mortality rates are highest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
Self-citationSpread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
Self-citationA molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Ariey, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier, C., Ma, L., et al. (2014) · Nature · doi:10.1038/nature12876 · Cited by 2,090
Self-citationThe Role of Hemocytes in Anopheles gambiae Antiplasmodial Immunity
Ramirez, J. L., Garver, L. S., Brayner, F. A., Alves, L. C., Rodrigues, J., Molina-Cruz, A., & Barillas-Mury, C. (2014) · Journal of Innate Immunity · doi:10.1159/000353765 · Cited by 1,084
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67176-0 · Cited by 1,050
Dondorp, A. M., Fanello, C. I., Hendriksen, I. C., Gomes, E., Seni, A., Chhaganlal, K. D., Bojang, K., Olaosebikan, R., Anunobi, N., Maitland, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61924-1 · Cited by 1,022
Self-citationEmergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
Phyo, A. P., Nkhoma, S., Stepniewska, K., Ashley, E. A., Nair, S., McGready, R., ler Moo, C., Al-Saai, S., Dondorp, A. M., Lwin, K. M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60484-x · Cited by 924
Self-citationMefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price, R. N., Uhlemann, A.-C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., Patel, R., Laing, K., Looareesuwan, S., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16767-6 · Cited by 853
K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates
Straimer, J., Gnädig, N. F., Witkowski, B., Amaratunga, C., Duru, V., Ramadani, A. P., Dacheux, M., Khim, N., Zhang, L., Lam, S., et al. (2015) · Science · doi:10.1126/science.1260867 · Cited by 728
Self-citationGenome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system
Ghorbal, M., Gorman, M., Macpherson, C. R., Martins, R. M., Scherf, A., & Lopez-Rubio, J.-J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2925 · Cited by 653
Cited by
Haldar, K., Bhattacharjee, S., & Safeukui, I. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.161 · Cited by 431
Quan, J., Langelier, C., Kuchta, A., Batson, J., Teyssier, N., Lyden, A., Caldera, S., McGeever, A., Dimitrov, B., King, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz418 · Cited by 261
Antimalarial drug resistance in Africa: the calm before the storm?
Conrad, M. D., & Rosenthal, P. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30261-0 · Cited by 255
Metadata
- Authors
- Fairhurst, R. M., & Dondorp, A. M.
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2016-05-06
- Volume
- 4
- Issue
- 3
- ISSN
- 2165-0497 (ISSN-L)
- OpenAlex
- W2467614481
- Cited by
- 303
- References
- 79
- FWCI
- 28.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.